Abbvie's blockbuster IL-23 inhibitor "Risankizumab" has been approved for marketing in China
I'm PortAI, I can summarize articles.
Abbvie's IL-23 inhibitor "Risankizumab" was approved for marketing by the National Medical Products Administration (NMPA) of China on March 10, for use in adult patients with moderate to severe active Crohn's disease. This drug is aimed at patients who have inadequate response, loss of response, or intolerance to conventional therapies or biologics. Risankizumab is a humanized monoclonal antibody that treats related chronic immune diseases by selectively antagonizing IL-23
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments